Status: Recruiting
R-PMDT Regimen in Newly Diagnosed PCNSL
A total of six cycles of the R-PMDT regimen (rituximab, pirtobrutinib, high-dose methotrexate, dexamethasone, and thiotepa) will be administered to patients with newly diagnosed primary central nervous system lymphoma (PCNSL). The primary objective is to assess the overall response rate (ORR) of R-PMDT. Secondary objectives include evaluating the complete response rate, progression-free survival (PFS), overall survival (OS), and safety.
Participants needed: 33
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Zou DehuiUpdated: May 22, 2026Locations: 1
Eligibility criteria
Newly diagnosed primary central nervous system diffuse large B-cell lymphoma [+6]
Prior anti-lymphoma therapy other than corticosteroids. [+7]